Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Clene Nanomedicine Announces Upcoming Presentations at the Maxim Group LLC Inaugural 2021 .
Clene Inc.March 10, 2021 GMT
SALT LAKE CITY, March 10, 2021 (GLOBE NEWSWIRE) Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on the treatment of neurodegenerative disease using nanocatalysis, today has featured its publicly filed business overview and corporate presentation on M-Vest.com and announced upcoming presentations at the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Conference hosted by M Vest LLC.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at .
Clene Inc.February 19, 2021 GMT
SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it will present updated interim data from its REPAIR-MS study and updated blinded interim data from its VISIONARY-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis’ ACTRIMS Forum 2021 (“ACTRIMS”) taking place virtually from February 25-27, 2021.
Cerevance Appoints Naidong Ye, Ph.D., As Vice President and Head of Chemistry, Manufacturing and Controls Will lead scale-up and production as Cerevance advances multiple clinical-stage programs
February 10, 2021 10:17 ET | Source: Cerevance Cerevance Boston, Massachusetts, UNITED STATES
BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Naidong Ye, Ph.D., a seasoned chemist with extensive pharmaceutical industry experience, as vice president and head of chemistry, manufacturing and controls (CMC).
Prior to joining Cerevance, Dr. Ye served as vice president of CMC for Millendo Therapeutics, a clinical stage biopharmaceutical company focused on developing novel treatments for endocrine diseases. While at Millendo, Dr. Ye was responsible for all CMC-related activities, including two late-stage program
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cerevance Appoints Carrie Ann Cook As Chief Business Officer
CerevanceFebruary 1, 2021 GMT
BOSTON, Feb. 01, 2021 (GLOBE NEWSWIRE) Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer effective February 1, 2021.
Ms. Cook most recently served as senior vice president/global head of business development at CANbridge Pharmaceuticals Inc., in Cambridge, MA. Prior to this position, she served as senior director, center for external innovation, rare disease, at Takeda Pharmaceuticals, where she led and executed research and development transactions. Ms. Cook previously served as head of global business development & licensing, MS, medical devices and global health at E
Home / Top News / Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis
Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis
Resulting patent to cover methods of
using Clene’s lead candidate CNM-Au8, now in Phase 2 and 3 trials for Multiple Sclerosis (MS) and Amyotrophic lateral sclerosis (ALS)
Latest patent allowance adds to Clene’s robust IP estate including over 130 patents issued and pending applications
SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly-owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, was issued a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its invention for using its patented clean-surfaced gold nanocrystal